Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:13333556" >
Enhanced immunogeni...
Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1
-
Nordstrom, EKL (författare)
-
- Forsell, MNE (författare)
- Karolinska Institutet
-
Barnfield, C (författare)
-
visa fler...
-
Bonin, E (författare)
-
Hanke, T (författare)
-
Sundstrom, M (författare)
-
- Karlsson, GB (författare)
- Karolinska Institutet
-
- Liljestrom, P (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Microbiology Society, 2005
- 2005
- Engelska.
-
Ingår i: The Journal of general virology. - : Microbiology Society. - 0022-1317 .- 1465-2099. ; 86:Pt 2, s. 349-354
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- With the human immunodeficiency virus type 1 (HIV-1) epidemic expanding at increasing speed, development of a safe and effective vaccine remains a high priority. One of the most central vaccine platforms considered is plasmid DNA. However, high doses of DNA and several immunizations are typically needed to achieve detectable T-cell responses. In this study, a Semliki Forest virus replicon DNA vaccine designed for human clinical trials, DREP.HIVA, encoding an antigen that is currently being used in human trials in the context of a conventional DNA plasmid, pTHr.HIVA, was generated. It was shown that a single immunization of DREP.HIVA stimulated HIV-1-specific T-cell responses in mice, suggesting that the poor immunogenicity of conventional DNA vaccines may be enhanced by using viral replicon-based plasmid systems. The results presented here support the evaluation of Semliki Forest virus replicon DNA vaccines in non-human primates and in clinical studies.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas